Valneva (VALN) said Tuesday that, together with Instituto Butantan, it has launched a pilot vaccination program in Brazil using its chikungunya vaccine, Ixchiq.
The program, which will serve as the basis for post-marketing commitment studies, will be implemented in ten Brazilian municipalities as part of a partnership between Instituto Butantan and the Brazilian Ministry of Health, the company said.
The vaccine was granted marketing approval in Brazil for use in adults in April, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments